

Influence of different IgG anticardiolipin antibody cutâ syndrome classification

Journal of Thrombosis and Haemostasis

6, 1693-1696

DOI: [10.1111/j.1538-7836.2008.03121.x](https://doi.org/10.1111/j.1538-7836.2008.03121.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	La recherche des facteurs biologiques de risque Ã©tablis de maladie thromboembolique veineuse : Ã©tat des connaissances et consÃ©quences pour la pratique en biologie clinique. Sang Thrombose Vaisseaux, 2009, 21, 012-039.	0.1	7
2	Accuracy of the First Fully Automated Method for Anti-Cardiolipin and Anti-Î²2 Glycoprotein I Antibody Detection for the Diagnosis of Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2009, 1173, 21-27.	3.8	20
3	Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery "spontaneous" HIT. Journal of Thrombosis and Haemostasis, 2009, 7, 499-501.	3.8	50
4	More on: the debate on antiphospholipid syndrome classification criteria. Journal of Thrombosis and Haemostasis, 2009, 7, 501-502.	3.8	11
5	Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial. Journal of Thrombosis and Haemostasis, 2009, 7, 503-504.	3.8	5
7	Antiphospholipid antibodies in critical illness. Critical Care Medicine, 2010, 38, S51-S56.	0.9	11
8	Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2010, 8, 237-242.	3.8	527
9	Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus, 2010, 19, 428-431.	1.6	34
10	"Criteria" aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus, 2011, 20, 182-190.	1.6	122
11	APS "controversies in diagnosis and management, critical overview of current guidelines. Thrombosis Research, 2011, 127, S51-S52.	1.7	22
14	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine, 2011, 270, 110-122.	6.0	91
15	Antiphospholipid syndrome: interpretation of laboratory data. Journal of Thrombosis and Haemostasis, 2011, 9, 402-403.	3.8	14
16	High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstetrica Et Gynecologica Scandinavica, 2011, 90, 1428-1433.	2.8	60
17	Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus, 2012, 21, 787-789.	1.6	29
18	Definition and significance of high positivity aCL ELISA. Lupus, 2012, 21, 725-726.	1.6	5
19	Interpretation of laboratory data and need for reference laboratories. Lupus, 2012, 21, 732-733.	1.6	9
20	What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?. Seminars in Thrombosis and Hemostasis, 2012, 38, 322-327.	2.7	57
21	Current International Initiatives in Antiphospholipid Antibody Testing. Seminars in Thrombosis and Hemostasis, 2012, 38, 360-374.	2.7	24

#	ARTICLE	IF	CITATIONS
22	Antiphospholipid antibody profiling – Time for a new technical approach?. <i>Autoimmunity Reviews</i> , 2012, 11, 821-826.	5.8	39
23	The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2012, 413, 911-913.	1.1	17
24	Antiphospholipid antibodies: Evaluation of the thrombotic risk. <i>Thrombosis Research</i> , 2012, 130, S37-S40.	1.7	48
25	Antiphospholipid Syndrome: Changing Knowledge During the Time – The –Four –Pattern. , 2012, , .		0
26	International consensus guidelines on anticardiolipin and anti-β ₂ glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies. <i>Arthritis and Rheumatism</i> , 2012, 64, 1-10.	6.7	163
27	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. <i>Rheumatology</i> , 2013, 52, 501-509.	1.9	44
28	Analytical Detection Capabilities of Immunoassay-Based Antiphospholipid Antibody Tests: Do They Matter?. <i>Drug Development Research</i> , 2013, 74, 575-581.	2.9	2
29	Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays. <i>Methods in Molecular Biology</i> , 2013, 992, 387-405.	0.9	9
30	Antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 675-680.	2.5	77
31	Correct laboratory approach to APS diagnosis and monitoring. <i>Autoimmunity Reviews</i> , 2013, 12, 832-834.	5.8	59
32	Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1527-1531.	3.8	94
33	Diagnosis of antiphospholipid syndrome in routine clinical practice. <i>Lupus</i> , 2013, 22, 18-25.	1.6	112
34	Comparison of modern analyzers for the detection of antiphospholipid antibodies in patients with SLE. <i>Laboratoriums Medizin</i> , 2013, 37, 139-145.	0.6	0
35	Index of circulating anticoagulant cut-off value establishment in activated partial thromboplastin time mixing test for lupus anticoagulant diagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1919-1922.	3.8	10
36	Automated, semi-automated, and manual analyses of anti-cardiolipin and anti-β ₂ glycoprotein I antibodies in women with a history of miscarriage. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 150-162.	1.3	4
37	Thrombotic Risk in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 741-746.	2.7	21
38	The future of treatment for antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 41-57.	0.3	0
39	Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2034-2037.	3.8	15

#	ARTICLE	IF	CITATIONS
40	Antiphospholipid antibody testing and standardization. International Journal of Laboratory Hematology, 2014, 36, 352-363.	1.3	78
41	Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 792-795.	3.8	175
42	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930.	5.8	224
43	Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thrombosis and Haemostasis, 2015, 113, 13-19.	3.4	81
44	Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfusion and Apheresis Science, 2015, 53, 269-278.	1.0	17
45	Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome. Medicine (United States), 2015, 94, e2059.	1.0	28
46	Antiphospholipid syndrome: antibodies to Domain 1 of Î²2â€¦glycoprotein 1 correctly classify patients at risk. Journal of Thrombosis and Haemostasis, 2015, 13, 782-787.	3.8	113
47	Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1265-70.	2.3	27
48	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clinica Chimica Acta, 2015, 446, 201-205.	1.1	38
49	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-Î²2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1083-9.	2.3	32
51	A contribution to detection of anticardiolipin and anti-Î²2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. Clinica Chimica Acta, 2015, 446, 93-96.	1.1	6
52	Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?. Journal of Rheumatology, 2015, 42, 158-160.	2.0	12
54	Antiphospholipid Antibody Syndrome-Diagnostic Issues of Lupus Anticoagulants. Journal of Hematology & Thromboembolic Diseases, 2016, 4, .	0.1	0
55	A Clinical Approach for Defining the Threshold between Low and Medium Anti-Cardiolipin Antibody Levels for QUANTA Flash Assays. Antibodies, 2016, 5, 14.	2.5	10
56	Role of anti-Î²domain 1â€¦glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2016, 14, 1779-1787.	3.8	72
57	Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. Journal of Reproductive Immunology, 2016, 115, 14-19.	1.9	49
58	Characteristics of Chinese patients with antiphospholipid syndrome and the ability of lupus anticoagulant assays to identify them. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1787-1791.	2.3	0
59	APS - Diagnostics and challenges for the future. Autoimmunity Reviews, 2016, 15, 1031-1033.	5.8	29

#	ARTICLE	IF	CITATIONS
60	Laboratory testing for antiphospholipid syndrome. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 27-31.	1.3	22
61	Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 555-560.	0.2	1
62	Association of anticardiolipin, antiphosphatidylserine, anti- β_2 glycoprotein I, and antiphosphatidylcholine autoantibodies with canine immune thrombocytopenia. <i>BMC Veterinary Research</i> , 2016, 12, 106.	1.9	2
63	The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. <i>Joint Bone Spine</i> , 2016, 83, 167-171.	1.6	22
65	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 562-571.	2.7	89
67	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <i>Autoimmunity Reviews</i> , 2017, 16, 1103-1108.	5.8	14
68	Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies. <i>Methods in Molecular Biology</i> , 2017, 1646, 185-199.	0.9	5
69	Solid Phase Immunoassay for the Detection of Anti- β_2 Glycoprotein I Antibodies. <i>Methods in Molecular Biology</i> , 2017, 1646, 201-215.	0.9	4
70	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 890-898.	2.3	49
71	Antiphospholipid Antibodies and Reproduction. , 0, , 113-123.		0
72	Antiphospholipid syndrome characteristics and adverse pregnancy outcomes after 20 weeks of pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 142, 214-220.	2.3	6
73	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	6.5	60
74	Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 809-813.	3.8	194
75	Clinical and laboratory characteristics of isolated lupus anticoagulants. <i>Thrombosis Research</i> , 2018, 165, 51-53.	1.7	9
76	Laboratory Diagnostics of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 439-444.	2.7	23
77	The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti- β_2 Glycoprotein I and Anti-Cardiolipin Antibodies. <i>Medical Science Monitor</i> , 2018, 24, 6816-6822.	1.1	6
78	Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti- β_2 -glycoprotein I antibodies: a systematic evaluation according to the guidelines. <i>Lupus</i> , 2018, 27, 1446-1454.	1.6	6
79	Assessment of diagnostic methods for the detection of anticardiolipin and anti- β_2 glycoprotein I antibodies in patients under routine evaluation for antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2018, 485, 7-13.	1.1	8

#	ARTICLE	IF	CITATIONS
80	Clinical value of anti-domain IÎ²2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. <i>Clinica Chimica Acta</i> , 2018, 485, 74-78.	1.1	13
81	Identification of high thrombotic risk triple-â€positive antiphospholipid syndrome patients is dependent on anti-â€cardiolipin and anti-â€2glycoprotein I antibody detection assays. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2016-2023.	3.8	51
82	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , 2018, 169, 35-40.	1.7	31
83	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. <i>Journal of Autoimmunity</i> , 2018, 93, 124-130.	6.5	26
84	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	8.0	95
85	Influence of anticardiolipin and anti-â€2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 515-527.	2.3	21
86	Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2019, 82, e13185.	1.2	14
87	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. <i>Autoimmunity Reviews</i> , 2019, 18, 561-563.	5.8	25
88	IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. <i>Thrombosis Research</i> , 2019, 177, 157-160.	1.7	30
89	Detection of Anti-Cardiolipin and Anti-Î²2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms. <i>Thrombosis and Haemostasis</i> , 2019, 119, 797-806.	3.4	30
90	Whatâ€™s new in obstetric antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 421-425.	2.5	8
91	Laboratory Evaluation of Antiphospholipid Syndrome. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 553-565.	1.4	6
92	Management of pregnant women with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 347-358.	3.0	18
93	Clinical profiles and risk assessment in patients with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 73-81.	3.0	10
94	Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 036-043.	3.4	11
95	A glimpse into the history of description of the antiphospholipid syndrome. <i>Lupus</i> , 2020, 29, 1493-1502.	1.6	0
96	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	1.6	27
97	Testing for antiphospholipid antibodies: Advances and best practices. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 49-58.	1.3	22

#	ARTICLE	IF	CITATIONS
98	Anti-phospholipid antibodies and reproductive failures. American Journal of Reproductive Immunology, 2021, 85, e13258.	1.2	13
99	The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics. Archives of Gynecology and Obstetrics, 2021, 303, 455-461.	1.7	10
100	Does incomplete obstetric antiphospholipid syndrome really exist?. Medicina Clínica, 2021, 156, 515-519.	0.6	4
101	Location of recurrent cardiovascular events and anticardiolipin antibodies. European Journal of Clinical Investigation, 2021, 51, e13533.	3.4	3
102	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. Expert Review of Hematology, 2021, 14, 457-466.	2.2	4
103	Does incomplete obstetric antiphospholipid syndrome really exist?. Medicina Clínica (English Edition), 2021, 156, 515-519.	0.2	0
104	Antiphospholipid antibodies quantification using ALBIA technology: how to define an optimal cutoff?. Clinical Chemistry and Laboratory Medicine, 2021, 59, e454-e457.	2.3	1
105	Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1950-1953.	2.3	13
106	Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). Klinicheskaya Laboratornaya Diagnostika, 2021, 66, 546-551.	0.5	1
107	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. Biomedicines, 2021, 9, 122.	3.2	5
108	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	1.9	41
109	Diagnosis and therapy of antiphospholipid syndrome. Polish Archives of Internal Medicine, 2015, 125, 672-677.	0.4	15
110	Task Force Report on "Criteria" Antiphospholipid Antibody Tests. , 2012, , 117-132.		0
111	Antiphospholipid Antibodies " Detection and Clinical Importance. , 0, , .		0
112	THE IX EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES. A BRIEF REVIEW. Nauchno-Prakticheskaya Revmatologiya, 2014, 52, 115.	1.0	2
114	Pregnancy Morbidity Associated with Thrombophilias: Late Placenta-Mediated Obstetric Complications. , 2015, , 139-158.		0
115	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity, 2021, 4, 100134.	4.0	21
116	APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome. International Journal of Clinical and Experimental Pathology, 2012, 5, 210-5.	0.5	12

#	ARTICLE	IF	CITATIONS
117	Antiphospholipid antibodies and idiopathic infertility. <i>Lupus</i> , 2022, 31, 347-353.	1.6	5
119	Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
120	Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature. <i>Clinical Rheumatology</i> , 0, , .	2.2	0
121	Antiphospholipid Syndrome: State of the Art of Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	1
122	Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation. <i>Rheumatology</i> , 0, , .	1.9	0
123	Quantification of Antiphospholipid Antibodies: The Importance of Using an Appropriate Methodology for Each Clinical Profile. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17373.	4.1	0